Ryan Hartman
Primary Care · Nashville, TNNPI 1942948690
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,765 of the $11,133 with a category attached, or 87.7%. It is spread thinly across 43 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,416, more than ten times the $96 reported in 2022. Among primary care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Insulet Corporation$964
- Medtronic$898
- Novo Nordisk$880
- Senseonics, Incorporated$800
- Xeris Pharmaceuticals, Inc.$680
- plus $6K from 37 others
What the payments were for
- Speaking & faculty fees$8007%
- Travel & lodging$5115%
- Food & beverage$9,76588%
- Education$320%
- Gifts$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$800
- CeQur Simplicity$629
- MINIMED 780G$495
- Omnipod$353
- DEXCOM G7 GSS (161)$146
- TWIIST$130
How this compares
$11,133 in reported general payments places this provider in the 95th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 448 | $624,945 |
| MounjaroTirzepatide | 242 | $330,071 |
| JardianceEmpagliflozin | 199 | $198,566 |
| Tresiba Flextouch U-200Insulin Degludec | 114 | $138,946 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $103,523 |
| TrulicityDulaglutide | 53 | $64,265 |
| RybelsusSemaglutide | 26 | $40,508 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $32,110 |
| FarxigaDapagliflozin Propanediol | 24 | $30,771 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $22,040 |
| Novolog FlexpenInsulin Aspart | 60 | $20,738 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $17,517 |
| Repatha SureclickEvolocumab | 19 | $15,744 |
| NovologInsulin Aspart | 36 | $13,671 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $12,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $880 | $679,124510 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,234 | $396,587311 claims |
| Boehringer IngelheimJardiance | $158 | $198,566199 claims |
| AstraZenecaFarxiga | $176 | $30,77124 claims |
| AbbVieSynthroid | $84 | $1,94326 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $119 | $60055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 primary care providers in Tennessee.
Other primary care in Nashville
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Stephanie MitchellNashville$2K
- Oumy NiangNashville$2K
- Rae TalleyNashville$1K
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Reena BhaktaMurfreesboro$12K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.